Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Clinically meaningful activity in favor of investigational nelipepimut-S (NeuVax) + Herceptin arm Clinically and statistically significant efficacy in triple negative breast cancer (TNBC) cohort;...
-
NEW YORK, March 21, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group Inc., (Nasdaq:SLS) (SELLAS), a clinical-stage biopharmaceutical company focused on novel cancer immunotherapies for a broad...
-
- Galinpepimut-S (GPS) induced immune activation against Wilms tumor-1 (WT1) antigen as well as multifunctional cross-epitope T-cell reactivity in patients with aggressive multiple myeloma -...
-
NEW YORK, March 15, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on novel cancer...
-
NEW YORK, March 13, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group Inc., (Nasdaq:SLS) (SELLAS), a clinical-stage biopharmaceutical company focused on novel cancer immunotherapies for a broad...
-
- Financing Will Support Advancement of its Late-Stage Immuno-Oncology Pipeline - - Lead Candidate, Galinpepimut-S (GPS), On-Target for Initiation of Phase 3 Acute Myeloid Leukemia (AML) Study and...
-
NEW YORK, March 05, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group Inc., (Nasdaq:SLS) (SELLAS), a clinical-stage biopharmaceutical company focused on novel cancer immunotherapies for a broad...
-
NEW YORK, Feb. 27, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group Inc. (Nasdaq:SLS) (SELLAS), a clinical-stage biopharmaceutical company focused on novel cancer immunotherapies for a broad...
-
- BIO CEO & Investor Conference on February 13 -- RBC Capital Markets Healthcare Conference on February 21 - NEW YORK, Feb. 06, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group Inc.,...
-
NEW YORK, Jan. 24, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq:SLS) (SELLAS) today announced that an abstract highlighting the detailed description of antigen-specific immune...